CliffBio
small molecule

QFITLIA

FITUSIRAN SODIUM

Loss of exclusivityDecember 2036latest FDA-listed patent expiry
CompanyGenzyme →View the full company profile on CliffBio

Drug detail

Brand nameQFITLIA
Active ingredientFITUSIRAN SODIUM
StrengthEQ 20MG BASE/0.2ML (EQ 20MG BASE/0.2ML)
Dosage formSOLUTION
RouteSUBCUTANEOUS
ModalitySmall molecule
FDA approvalMarch 2025
Marketing statusRX

Listed patents

PatentExpiresType
11091759December 2036use U-4165
9127274March 2033substance, product
9376680March 2033substance, product

Regulatory exclusivity

CodeExpires
ODE-510March 2032
ODE-511March 2032
NCEMarch 2030

More from Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

QFITLIA patent cliff — loss of exclusivity December 2036 | CliffBio